Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AEterna Zentaris Inc. (USA) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AEZS
Nasdaq
8731
https://www.zentaris.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AEterna Zentaris Inc. (USA)
Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19
- Jan 17th, 2023 5:53 pm
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
- Jan 17th, 2023 1:05 pm
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
- Jan 11th, 2023 6:00 pm
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
- Jan 10th, 2023 1:05 pm
Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates
- Nov 3rd, 2022 2:15 pm
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
- Nov 3rd, 2022 12:05 pm
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
- Aug 29th, 2022 12:00 pm
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
- Aug 3rd, 2022 9:30 pm
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Jul 28th, 2022 2:02 pm
Aeterna Zentaris Announces Effective Date of Share Consolidation
- Jul 18th, 2022 9:06 pm
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
- Jul 15th, 2022 8:15 pm
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
- Jul 6th, 2022 8:05 pm
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
- Jun 21st, 2022 8:01 pm
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
- Jun 13th, 2022 12:00 pm
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
- Jun 9th, 2022 12:00 pm
Here's Why We're Watching Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation
- Jun 3rd, 2022 10:58 am
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
- May 25th, 2022 12:00 pm
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
- May 18th, 2022 12:00 pm
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
- May 16th, 2022 12:00 pm
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
- May 12th, 2022 12:05 pm
Scroll